To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
9 Current news of Universität Tübingen
rss
Immunity drives cancer into permanent growth arrest
05-02-2013
Martin Röcken and his team at the Department of Dermatology, Eberhard Karls University Tuebingen, found that anti-cancer immunity is capable of driving cancers and single cancer cells into a permanent growth arrest. Scientifically this permanent growth arrest is called senescence. As complete ...
Kidney Cancer Vaccine Successful in Clinical Trials
31-07-2012
Researchers at the University of Tübingen and immatics biotechnologies GmbH – a start-up by Tübingen scientists – have published the results of two clinical studies using the kidney-cancer vaccine IMA901 in the latest edition of Nature Medicine. IMA901 is used to treat patients with cancer of ...
New insights into the genetic architecture of Parkinson’s disease
19-07-2012
Scientists at the Hertie Institute for Clinical Brain Research and the University Hospital of Tübingen have – as leaders of a large, international joint study – demonstrated the significance of new genetic risk factors for Parkinson’s disease in different population groups. The study is based ...
Peripheral Induction of Alzheimer-Like Brain Pathology in Mice
25-10-2010
Pathological protein deposits linked to Alzheimer's disease and cerebral amyloid angiopathy can be triggered not only by the administration of pathogenic misfolded protein fragments directly into the brain but also by peripheral administration outside the brain. This is shown in a new study ...
The Key that Fits: New Technique To Trace Disease-Related Agents
09-03-2010
In the development of new drugs, photoaffinity labels (PALs) are a versatile tool to investigate the interaction between a receptor and a drug or a ligand. Researchers working with Stephanie Grond at the University of Tübingen and Paultheo von Zezschwitz at the University of Marburg have now ...
Warum die Evolution manchmal nur langsam vorankommt
Ein theoretisches Modell erklärt die gebremste Entwicklung von Mikrolebewesen
12-08-2008
In den Sedimenten der Tiefsee gibt es ein besonderes Archiv der Evolution: Dort sind die Überreste von einst frei im Wasser schwebenden Kleinstlebewesen, dem sogenannten Mikroplankton, zu finden. Über viele Millionen vergangene Jahre haben sich die Mikrofossilien in gut datierbaren Schichten ...
Pharming receives funding for development of new treatments for premature ageing diseases
29-01-2008
Pharming Group NV announced that its wholly owned subsidiary DNage will head a collaborative Research and Development effort to identify novel biomarkers and therapeutic targets, and to develop therapeutics for the treatment of premature ageing diseases. The consortium has been granted a ...
Cooperation on the Development of a Malaria Vaccine
The malaria vaccine GMZ2 to be tested in a Phase I clinical trial in Tübingen
23-12-2005
Vakzine Projekt Management GmbH (VPM) and the European Malaria Vaccine Initiative (EMVI) are cooperating in compiling and submitting the Phase I clinical trial application of malaria vaccine GMZ2 to the Paul-Ehrlich-Institute and to the Ethics Committee Tübingen, Germany. In addition, VPM ...
SEQUENOM Announces Gene Expression Agreement With the University of Tuebingen
MassARRAY(TM) Compact System Reference Site Established
18-08-2004
SEQUENOM, Inc. announced an agreement with the Institute of Medical Genetics and the Microarray Facility at the University of Tuebingen in Germany for SEQUENOM's MassARRAY Quantitative Gene Expression (QGE) application. The Institute is one of the largest users of expression profiling arrays ...
Page 1 From 1
Netmeeting
